<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00132210</url>
  </required_header>
  <id_info>
    <org_study_id>BN-102/02</org_study_id>
    <nct_id>NCT00132210</nct_id>
  </id_info>
  <brief_title>Pegylated Interferon Therapy for Acute Hepatitis C Infection in HIV-infected Patients</brief_title>
  <official_title>Pegylated Interferon Therapy for Acute Hepatitis C Infection in HIV-infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bonn</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether pegylated interferon therapy is effective
      to treat acute hepatitis C infection in HIV-coinfected individuals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:HIV-infected individuals are at higher risk of developing a chronic course of
      hepatitis C after infection. Moreover, chronic hepatitis C is less well treatable in
      HIV-Coinfected than in hepatitis C monoinfected patients. There is basic research and
      clinical data on hepatitis C mono-infection supporting high sustained response rates of
      hepatitis C when treatment is started in the acute phase of infection.

      Aim of the study: To determine whether pegylated interferon therapy is effective to treat
      acute hepatitis C infection in HIV-coinfected individuals.

      Methods: Prospective, open-label, historical controlled trial. Eligible subjects are treated
      over 24 weeks with a pegylated interferon at standard dose. Weight-adjusted ribavirin
      comedication is recommended for HCV-genotypes 1 and 4. Treatment will be withheld for 12
      weeks in order to allow spontaneous resolution in subjects with clinical symptomatic
      hepatitis C infection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Negative hepatitis C ribonucleic acid (HCV-RNA) in peripheral serum</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Normal liver enzymes</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Negative HCV-RNA</measure>
    <time_frame>Week 12 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normal liver enzymes</measure>
    <time_frame>Week 12 and 48</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hepatitis C</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated interferon</intervention_name>
    <description>Pegylated interferon alfa-2a or -2b in standard dosage Ribavirin in case of genotype 1 or 4 at 1000 or 1200 mg/d according to body weight ist recommended.</description>
    <other_name>Pegasys</other_name>
    <other_name>PegIntron</other_name>
    <other_name>Copegus</other_name>
    <other_name>Rebetol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented acute hepatitis C infection with detectable HCV-RNA (PCR-assay) and
             elevated serum alanine transferase (ALT) levels. An acute infection is defined by
             fulfilling two of the following 3 criteria within the preceding four months:

               1. known or suspected exposure to HCV,

               2. documented seroconversion to positivity for antibodies against HCV,

               3. a serum alanine transferase (ALT) level of more than 350 U/l with a documented
                  normal level during the year before infection.

          -  Documented HIV-infection

          -  CD4 cells &gt; 300 /µl

          -  Ability to understand and sign a written consent form

          -  Women of child-bearing age: negative pregnancy test

        Exclusion Criteria:

          -  Autoimmune hepatitis or other autoimmune disease

          -  Decompensated liver disease

          -  Decompensated renal disease, i.e. creatinine clearance &lt; 50 ml/min, according to
             Cockcroft-Gault

          -  Acute or chronic hepatitis B infection

          -  Acute infection with hepatitis A or other hepatotropic viruses

          -  New AIDS defining event less than 1 month prior to enrolment

          -  Malignancy other than cutaneous kaposi sarcoma treated with systemic chemo-therapy

          -  History of severe psychiatric conditions, in particular severe depression

          -  History of seizures

          -  History of organ transplantation

          -  Thyroid disease not medically compensable

          -  Severe heart disease

          -  Severe retinopathy

          -  Known allergy to the study drug or one of the galenic compounds

          -  Hypersensitivity to interferon a

          -  Thrombocytes &lt; 90 G/l, neutrophils &lt; 1.5 G/l, hemoglobin must not be &lt; 12g/dl (female)
             or &lt; 13 g/dl (male)

          -  Treatment with corticosteroids less than 3 months prior to enrolment

          -  Alcohol abuse or use of other recreational drugs

          -  Older than 65 years of age, younger than 18 years of age

          -  Pregnancy, breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jürgen K Rockstroh, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Medical Department I, University Hospital, Bonn University, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Vogel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Department I, University Hospital, Bonn University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Practice Hintsche</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice Bieniek</name>
      <address>
        <city>Berlin</city>
        <zip>10243</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice Dupke/Carganico/Baumgarten</name>
      <address>
        <city>Berlin</city>
        <zip>10439</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice Schranz</name>
      <address>
        <city>Berlin</city>
        <zip>10627</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice Freiwald/Rausch</name>
      <address>
        <city>Berlin</city>
        <zip>10777</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice Jessen</name>
      <address>
        <city>Berlin</city>
        <zip>10777</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice Kluschke</name>
      <address>
        <city>Berlin</city>
        <zip>12047</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ärzteforum Seestraße</name>
      <address>
        <city>Berlin</city>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice Center Kaiserdamm</name>
      <address>
        <city>Berlin</city>
        <zip>14057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Department I, University Hospital, Bonn University</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice Fenske</name>
      <address>
        <city>Hamburg</city>
        <zip>20146</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice Linnig</name>
      <address>
        <city>Hamburg</city>
        <zip>20359</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice Trein</name>
      <address>
        <city>Stuttgart</city>
        <zip>70197</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Vogel M, Bieniek B, Jessen H, Schewe CK, Hoffmann C, Baumgarten A, Kroidl A, Bogner JR, Spengler U, Rockstroh JK. Treatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases. J Viral Hepat. 2005 Mar;12(2):207-11.</citation>
    <PMID>15720537</PMID>
  </reference>
  <results_reference>
    <citation>Vogel M, Nattermann J, Baumgarten A, Klausen G, Bieniek B, Schewe K, Jessen H, Boesecke C, Rausch M, Lutz T, Fenske S, Schranzo D, Kümmerle T, Schuler C, Theisen A, Mayr C, Seidel T, Rockstroh JK. Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals. Antivir Ther. 2006;11(8):1097-101.</citation>
    <PMID>17302380</PMID>
  </results_reference>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2005</study_first_submitted>
  <study_first_submitted_qc>August 17, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2005</study_first_posted>
  <last_update_submitted>October 20, 2010</last_update_submitted>
  <last_update_submitted_qc>October 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2010</last_update_posted>
  <responsible_party>
    <name_title>Jürgen K. Rockstroh</name_title>
    <organization>Bonn University</organization>
  </responsible_party>
  <keyword>acute hepatitis C</keyword>
  <keyword>HIV</keyword>
  <keyword>pegylated interferon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

